Kristie A. Blum
YOU?
Author Swipe
View article: Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis
Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis Open
Introduction: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare subtype of diffuse large B-cell lymphoma characterized by unique pathobiologic features and historically poor outcomes. Recent evidence presented at ASH suggest…
View article: A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma Open
A.S.L, D.J., and H.J.L. contributed equally I.W.F., J.S.A., and A.F.H. contributed equally Introduction: Maximizing treatment efficacy while minimizing late effects is critical in patients with early stage classic Hodgkin lymphoma (cHL). W…
View article: Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma Open
N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the N…
View article: Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia
Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia Open
Background: Adolescent and Young Adult (AYA) patients, historically defined by the National Cancer Institute as patients between 15-39 years, diagnosed with cancer are at risk for increased mortality compared with younger patients. Age 10 …
View article: Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era Open
In the pre–novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI)…
View article: A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma Open
Not available.
View article: P1071: COMBINATION OF PD-1 INHIBITION WITH IMMUNOMODULATORY DRUG TREATMENT IN HODGKIN AND LARGE B-CELL LYMPHOMA: RESULTS FROM A PHASE I/II STUDY
P1071: COMBINATION OF PD-1 INHIBITION WITH IMMUNOMODULATORY DRUG TREATMENT IN HODGKIN AND LARGE B-CELL LYMPHOMA: RESULTS FROM A PHASE I/II STUDY Open
Topic: 17. Hodgkin lymphoma - Clinical Background: Lenalidomide and nivolumab each have single agent activity in relapsed Hodgkin lymphoma (HL) and large B-cell lymphoma (LBCL) with potential for additive or synergistic activity. The immun…
View article: Efficacy of brentuximab consolidation by metabolic response in an international real‐world cohort of classic Hodgkin lymphoma at high risk for progression after ASCT
Efficacy of brentuximab consolidation by metabolic response in an international real‐world cohort of classic Hodgkin lymphoma at high risk for progression after ASCT Open
Background: Salvage chemotherapy and autologous stem cell transplant (ASCT) have cure rates of 60–70% in relapsed refractory (R/R) classic Hodgkin lymphoma (cHL). Pre-ASCT compete metabolic response (CMR) compared to partial metabolic resp…
View article: Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents
Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents Open
Introduction: Approximately 20% of patients (pts) with classic Hodgkin lymphoma (cHL) relapse after frontline therapy. Salvage chemotherapy and autologous stem cell transplant (ASCT) have cure rates of 60%–70%. Prior to brentuximab vedotin…
View article: Combination of the PD‐1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B‐cell Lymphoma: Results from a Phase I/II Study
Combination of the PD‐1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B‐cell Lymphoma: Results from a Phase I/II Study Open
Introduction: Lenalidomide (len) and nivolumab (nivo) each have single agent activity in relapsed Hodgkin lymphoma (HL) and large B-cell lymphoma (LBCL) with potential for additive or synergistic activity. The immunomodulatory properties o…
View article: NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826
NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826 Open
Peer Reviewed
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Fig. S4: Grade 3 or higher AEs of clinical interest by time to onset from first dose in the (A) first-line and (B) relapsed/refractory treatment settings
View article: Supplementary Appendix from Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Supplementary Appendix from Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Open
Supplementary Table S1: Patient disposition; Supplementary Table S2: Summary of adverse events; Supplementary Table S3: Response improvement and durability; Supplementary Table S4: Best response in patients who achieved PR with lymphocytos…
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Fig. S2: Overall survival in the following subgroups: (A) by number of prior lines of therapy; (B) by complex karyotype with del(17p) and without del(17p) in the relapsed/refractory setting; (C) with and without lymphocytosis…
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Fig. S3: All-grade AEs collected per protocol prior to June 2012 protocol amendment (median time on treatment 16 months) and grade 3 or higher or other specified AEs collected subsequent to amendment
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Table S2: Grade 3 or higher AEs in patients receiving ibrutinib in the first-line or relapsed/refractory treatment settings
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Fig. S4: Grade 3 or higher AEs of clinical interest by time to onset from first dose in the (A) first-line and (B) relapsed/refractory treatment settings
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Fig. S1: Progression-free survival in the following subgroups: (A) by number of prior lines of therapy; (B) by complex karyotype with del(17p) and without del(17p) in the relapsed/refractory setting; (C) with and without lymp…
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Table S3: Grade 3 or higher infections in patients receiving ibrutinib in the first-line or relapsed/refractory treatment settings
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Table S3: Grade 3 or higher infections in patients receiving ibrutinib in the first-line or relapsed/refractory treatment settings
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Table S1: Patient disposition and dose modification in patients receiving ibrutinib in the first-line and relapsed/refractory treatment settings
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Table S2: Grade 3 or higher AEs in patients receiving ibrutinib in the first-line or relapsed/refractory treatment settings
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Fig. S2: Overall survival in the following subgroups: (A) by number of prior lines of therapy; (B) by complex karyotype with del(17p) and without del(17p) in the relapsed/refractory setting; (C) with and without lymphocytosis…
View article: Data from Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Data from Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Open
Purpose: Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and migration. Ibrutinib has demonstrated single-agent efficacy and acceptable tol…
View article: Data from Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Data from Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Open
Purpose: Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and migration. Ibrutinib has demonstrated single-agent efficacy and acceptable tol…
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Table S4: Malignancies in patients receiving ibrutinib in the first-line or relapsed/refractory treatment settings
View article: Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Supplementary Fig. S1: Progression-free survival in the following subgroups: (A) by number of prior lines of therapy; (B) by complex karyotype with del(17p) and without del(17p) in the relapsed/refractory setting; (C) with and without lymp…
View article: Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study Open
Purpose:The safety and efficacy of ibrutinib, a once-daily Bruton's tyrosine kinase (BTK) inhibitor, in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was demonstrated in this phase Ib/II study. Extended follow-up up to …
View article: Supplementary Appendix from Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Supplementary Appendix from Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Open
Supplementary Table S1: Patient disposition; Supplementary Table S2: Summary of adverse events; Supplementary Table S3: Response improvement and durability; Supplementary Table S4: Best response in patients who achieved PR with lymphocytos…